U.S. Pastent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			09740191
	Filing Date		2000-12-19
	First Named Inventor Liang		-Chang Dong
	Art Unit		1615
Examiner Name Humo		Hume	era N. Sheikh
Attorney Docket Number		er	ARC2556N1

				U.S.	PATENTS		Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Relevan	Columns,Lines where nt Passages or Relevan Appear
	1	4034758		1997-07-12	Theeuwes		
	2	4256108		1981-03-17	Theeuwes		
	3	4800056		1989-01-24	Eckenhoff		
	4	5444041		1995-08-22	Owen		
	5	5652212		1997-07-29	Cavanak		
lf you wisl	h to a	dd additional U.S. Pater			lease click the Add button.		Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Relevan	Columns,Lines where nt Passages or Relevan Appear
	1						
If you wisl	h to a	i dd additional U.S. Publi	shed Ap	plication citatio	n information please click the Add	d button.	Add

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Foreign Document

Examiner Cite

No Number<sup>3</sup>

Initial\*

A

Е

Country

Code2 i

pplication Number		09740191
iling Date		2000-12-19
irst Named Inventor Liang		-Chang Dong
rt Unit		1615
xaminer Name	Hume	era N. Sheikh
Hornou Docket Numb	or	ADC2656N4

Name of Patentee or

Date Considered

Applicant of cited

Document

Pages, Columns, Lines

where Relevant Passages or Relevant

Figures Appear

	1		
If you wis	h to a	dd additional Foreign Patent Document citation information please click the Add button Add	
		NON-PATENT LITERATURE DOCUMENTS Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Тs
	1	Van Nostrand Reinhold Encyclopedia of Chemistry, 4th edition, Considere and Considere, editors, pp. 644-645, 1984	
	2	Pharmaceutoal Sciences by Remington, 17th edition, pp. 403-405, 1985	
	3	Encyclopeda of polymer science and technology, vol. 3, pp. 325-354, 1965	
If you wisl	h to a	dd additional non-patent literature document citation information please click the Add button Add	

Kind Publication

Code<sup>4</sup> Date

See finit Codes of USPTO Patent Documents at ivene USPTO CDV or MEPF 90.104. \* Enter office that issued the document, by the No-letter code (WIPO Standard ST3.) \* For Leganese patent for comments, the indication of the year of the region or the Emperor many precised the reviet intermed for payard for expert.

\*\*Yard of courrent by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*\*Applicant is to place a check mark there if Employs Indications a standard.\*\*

FXAMINER SIGNATURE

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09740191
Filing Date		2000-12-19
First Named Inventor	Liang	-Chang Dong
Art Unit		1615
Examiner Name	Hume	era N. Sheikh
Attorney Docket Number		ARC2556N1

42254

#### CERTIFICATION STATEMENT

Please see 37	CFR 1	.97 and	1.98 to make the	appropriate	selection(	s)	
---------------	-------	---------	------------------	-------------	------------	----	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 19/10/0. (more than three months prior to the filing of the information disclosure statement Sec 37 CFR 19/10/0.)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Adenike A Adehivi

. ✓ None

Name/Print

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.						
Signature	/Adenike Adebivi/	Date (YYYY-MM-DD)	2006-07-01			

Registration Number

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operament of Commence, P. 0. Box 1450, Alexandris, V.2.231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan, Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested in the patient of the pa

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing impaction of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was fled in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to public insepections or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.